Tag - Janney

Markets

Janney starts Y-mAbs Therapeutics at buy; fair value estimate $45

Janney Montgomery Scott initiated coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and fair value estimate of $45. The stock closed at $35.03 on April 30. Y-mAbs is developing immunotherapies for...

May 1, 2020

Markets

Janney starts Baudax Bio at buy; fair value estimate $12

Janney Montgomery Scott launched coverage of Baudax Bio (NASDAQ:BXRX) with a “buy” rating and fair value estimate of $12. The stock closed at $4.51 on Nov. 21. Baudax was spun out of Recro Pharma (NASDAQ:REPH) in a...

November 22, 2019

Markets

Janney starts Spero Therapeutics at buy; fair value estimate $27

Janney Montgomery Scott initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and fair value estimate of $27. The stock closed at $9.98 on Sept. 6. Analyst Esther Hong writes that her initiation is...

September 9, 2019

Markets

Janney starts Applied Genetic Technologies at buy; fair value estimate $13

Janney initiated coverage of Applied Genetic Technologies (NASDAQ:AGTC) with a “buy” rating and fair value estimate of $13. The stock closed at $3.20 on Sept. 5. “We see a highly attractive investment opportunity in...

September 6, 2019

Tag - Janney

Janney starts Y-mAbs Therapeutics at buy; fair value estimate $45

Janney starts Baudax Bio at buy; fair value estimate $12

Janney starts Spero Therapeutics at buy; fair value estimate $27

Janney starts Applied Genetic Technologies at buy; fair value estimate $13

General

More